Neurol. praxi. 2022;23(3):221-226 | DOI: 10.36290/neu.2021.094

Cognitive dysfunction in secondary progressive multiple sclerosis

MUDr. Radek Ampapa
Neurologické oddělení Nemocnice Jihlava

Cognitive dysfunction is among the less frequently investigated and diagnosed signs in multiple sclerosis (MS). Standard diagnostic processes used in routine neurological practice fail to sufficiently consider cognitive impairment. Cognitive dysfunction is more common in progressive MS variants and can have a significant impact on the patient's quality of life. Secondary progressive MS is a difficult-to-treat condition. Siponimod is the first drug which, in patients with secondary progressive MS, has been shown to reduce the progression of disability while having a positive effect on cognitive functions. Cognitive monitoring can prospectively be a new parameter which could be used to monitor treatment efficacy.

Keywords: secondary progressive multiple sclerosis, cognitive test, siponimod, SDMT.

Received: August 30, 2021; Revised: November 16, 2021; Accepted: November 28, 2021; Prepublished online: November 28, 2021; Published: June 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ampapa R. Cognitive dysfunction in secondary progressive multiple sclerosis. Neurol. praxi. 2022;23(3):221-226. doi: 10.36290/neu.2021.094.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Behrangi N, Fischbach F, Kipp M. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells. 2019;8(1):24. doi: 10.3390/cells8010024. PMID: 30621015; PMCID: PMC6356776. Go to original source... Go to PubMed...
    2. Benedict RH, Amato MP, Boringa J, et al. Brief International Cognitive Assessment for MS (BICAMS): International standards for validation. BMC Neurol. 2012;12:55. Go to original source... Go to PubMed...
    3. Benedict RH, Tomic D, Cree BA, et al. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses. Neurology. 2021;96(3):e376-e386. doi: 10.1212/WNL.0000000000011275. Epub 2020 Dec 16. PMID: 33328324. Go to original source... Go to PubMed...
    4. Ferrazzano G, Crisafulli SG, Baione V, et al. Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers. Front. Neurol. 2020. https://doi.org/10.1007/s00415-020-09964-4. Go to original source... Go to PubMed...
    5. Gillen KM, Mubarak M, Nguyen TD, Pitt D. Significance and In Vivo Detection of Iron-Laden Microglia in White Matter Multiple Sclerosis Lesions. Front Immunol. 2018;9:255. doi: 10.3389/fimmu.2018.00255. PMID: 29515576; PMCID: PMC5826076. Go to original source... Go to PubMed...
    6. Grzegorski T, Losy J. Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research. Rev Neurosci. 2017;28(8):845-860. doi: 10.1515/revneuro-2017-0011. PMID: 28787275. Go to original source... Go to PubMed...
    7. Kappos L, Bar-Or A, Cree BAC, et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170. PMID: 29576505. Go to original source... Go to PubMed...
    8. Koch M, Kingwell E, Rieckmann P, Tremlett H; UBC MS Clinic Neurologists. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(9):1039-1043. doi: 10.1136/jnnp.2010.208173. Epub 2010 Jul 16. PMID: 20639385. Go to original source... Go to PubMed...
    9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-911. doi: 10.1212/wnl.46.4.907. PMID: 8780061. Go to original source... Go to PubMed...
    10. Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72 Suppl 1:1-5. Go to original source... Go to PubMed...
    11. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183-193. doi: 10.1016/S1474-4422(14)70256-X. PMID: 25772897. Go to original source... Go to PubMed...
    12. Nakano K, Park K, Zheng R, et al. Leukoaraiosis Significan­tly Worsens Driving Performance of Ordinary Older Drivers. PloS one. 9. e108333 (2014). 10.1371/journal.pone.0108333. Go to original source... Go to PubMed...
    13. Papathanasiou A, Messinis L, Georgiou VL, Papathanasopoulos P. Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery. ISRN Neurol. 2014;2014:151379. doi: 10.1155/2014/151379. PMID: 25006497; PMCID: PMC3976849. Go to original source... Go to PubMed...
    14. Pitteri M, Romualdi C, Magliozzi R, et al. Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study. Mult Scler. 2017;23(6):848-854. doi: 10.1177/1352458516665496. Epub 2016 Aug 15. PMID: 27527906. Go to original source... Go to PubMed...
    15. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13(7):700-722. doi: 10.1111/j.1468-1331.2006.01342.x. PMID: 16834700. Go to original source... Go to PubMed...
    16. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006;5(4):343-354. doi: 10.1016/S1474-4422(06)70410-0. PMID: 16545751. Go to original source... Go to PubMed...
    17. Ruano L, Portaccio E, Goretti B, et al. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler. 2017;23(9):1258-1267. doi: 10.1177/ 1352458516674367. Epub 2016 Oct 13. PMID: 27738090. Go to original source... Go to PubMed...
    18. Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(1):67-75. doi: 10.1136/jnnp-2012-304333. Epub 2013 Mar 13. PMID: 23486991. Go to original source... Go to PubMed...
    19. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal. 2020;26(14):1816-1821. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.